The ultimate goal of our dedicated team of employees is to advance research for treatments of serious and life-threatening infections.

At the time of our company’s founding in 2005, we focused our energy on advancing our lead product candidate‚ ceftaroline fosamil. In 2007, we became a wholly-owned subsidiary of Forest Laboratories. The collaboration with Forest allows us to integrate and capitalize on our collective resources.

Ceftaroline fosamil, sold under the name Teflaro^®, was approved by the U.S. Food and Drug Administration in October 2010. To learn more, visit www.Teflaro.com.

We are also developing a novel IV beta-lactamase inhibitor, NXL104, known as avibactam. We are evaluating the potential combination of avibactam with ceftaroline. Beta-lactamase inhibition represents a mechanism for counteracting resistance and enhancing the spectrum of activity of beta-lactam antibiotics. Microbiology studies of avibactam in combination with ceftaroline have demonstrated that avibactam increases ceftaroline’s activity in vitro against beta-lactamase-producing gram-negative pathogens. We will be conducting further research to assess whether in vitro efficacy is duplicated in a clinical setting.

In addition, we are developing avibactam in combination with ceftazidime, a third generation cephalosporin with broad-spectrum activity. The utility of third and fourth generation cephalosporins are being increasingly eroded by the emergence of extended-spectrum beta-lactamase (ESBL)-producing bacteria. The combination of ceftazidime with avibactam may restore the activity of ceftazidime against beta-lactamase-producing gram-negative bacteria, including P. aeruginosa.

We conduct our business with the highest ethical standards. We believe that our ability to positively impact people’s health and save lives is directly linked to the quality of our employees and our research and development activities.